These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 33637024)

  • 21. Evolving therapeutic strategies for advanced hepatocellular carcinoma.
    Qureshi A; Michel M; Lerner J; Dasanu CA
    Expert Opin Pharmacother; 2021 Dec; 22(18):2495-2506. PubMed ID: 34252328
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunotherapy in Hepatocellular Carcinoma.
    Fulgenzi CAM; Talbot T; Murray SM; Silletta M; Vincenzi B; Cortellini A; Pinato DJ
    Curr Treat Options Oncol; 2021 Aug; 22(10):87. PubMed ID: 34424422
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Longo V; Brunetti O; Gnoni A; Licchetta A; Delcuratolo S; Memeo R; Solimando AG; Argentiero A
    Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31627433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapy for hepatocellular carcinoma.
    Huang A; Yang XR; Chung WY; Dennison AR; Zhou J
    Signal Transduct Target Ther; 2020 Aug; 5(1):146. PubMed ID: 32782275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.
    Kudo M
    Int J Clin Oncol; 2022 Jul; 27(7):1110-1119. PubMed ID: 35527313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging drugs for the treatment of hepatocellular carcinoma.
    Ayoub WS; Jones PD; Yang JD; Martin P
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma.
    Cersosimo RJ
    Am J Health Syst Pharm; 2021 Jan; 78(3):187-202. PubMed ID: 33211092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.
    Hiraoka A; Kumada T; Kariyama K; Takaguchi K; Atsukawa M; Itobayashi E; Tsuji K; Tajiri K; Hirooka M; Shimada N; Shibata H; Ishikawa T; Ochi H; Tada T; Toyoda H; Nouso K; Tsutsui A; Itokawa N; Imai M; Joko K; Hiasa Y; Michitaka K;
    Cancer Med; 2019 Jan; 8(1):137-146. PubMed ID: 30575325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies.
    Marquardt JU; Saborowski A; Czauderna C; Vogel A
    Target Oncol; 2019 Apr; 14(2):115-123. PubMed ID: 30805831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
    Woo HY; Yoo SY; Heo J
    Expert Opin Pharmacother; 2017 Jan; 18(1):35-44. PubMed ID: 27849399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
    Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape.
    Mody K; Abou-Alfa GK
    Curr Treat Options Oncol; 2019 Jan; 20(2):3. PubMed ID: 30635732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An update of treatments of hepatocellular carcinoma in patients refractory to sorafenib.
    Ielasi L; Sansone V; Granito A; Benevento F; De Lorenzo S; Tovoli F
    Drugs Today (Barc); 2018 Oct; 54(10):615-627. PubMed ID: 30398482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond.
    Amaro CP; Tam VC
    Curr Oncol; 2020 Nov; 27(Suppl 3):S173-S180. PubMed ID: 33343211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates.
    Shek D; Read SA; Nagrial A; Carlino MS; Gao B; George J; Ahlenstiel G
    Oncologist; 2021 Jul; 26(7):e1216-e1225. PubMed ID: 33818870
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib.
    Brunetti O; Gnoni A; Licchetta A; Longo V; Calabrese A; Argentiero A; Delcuratolo S; Solimando AG; Casadei-Gardini A; Silvestris N
    Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31640191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma.
    de Rosamel L; Blanc JF
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):175-190. PubMed ID: 28604110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nivolumab + Ipilimumab for patients with hepatocellular carcinoma previously treated with Sorafenib.
    Tsang J; Wong JSL; Kwok GGW; Li BCW; Leung R; Chiu J; Cheung TT; Yau T
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):589-598. PubMed ID: 33666530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in novel systemic therapies for advanced hepatocellular carcinoma.
    Carloni R; Rizzo A; Cusmai A; Palloni A; Federico AD; Marco MD; Massafra R; Fanizzi A; Palmiotti G; Brandi G
    Future Med Chem; 2022 Oct; 14(20):1455-1470. PubMed ID: 35997677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.